Mereo Biopharma Group Plc ADR’s recently made public that its Chief Executive Officer Scots-Knight Denise unloaded Company’s shares for reported $0.25 million on Sep 13 ’24. In the deal valued at $4.22 per share,60,046 shares were sold. As a result of this transaction, Scots-Knight Denise now holds 808,921 shares worth roughly $2.86 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Scots-Knight Denise sold 28,611 shares, generating $127,968 in total proceeds. Upon selling the shares at $4.47, the Chief Executive Officer now owns 868,967 shares.
Before that, Lewicki John A. sold 10,937 shares. Mereo Biopharma Group Plc ADR shares valued at $46,165 were divested by the Chief Scientific Officer at a price of $4.22 per share. As a result of the transaction, Lewicki John A. now holds 78,630 shares, worth roughly $0.28 million.
Robert W. Baird initiated its Mereo Biopharma Group Plc ADR [MREO] rating to an Outperform in a research note published on June 13, 2024; the price target was $8. Cantor Fitzgerald began covering MREO with “an Overweight” recommendation on August 12, 2022. BTIG Research started covering the stock on May 05, 2021. It rated MREO as “a Buy”.
Price Performance Review of MREO
On Friday, Mereo Biopharma Group Plc ADR [NASDAQ:MREO] saw its stock fall -7.59% to $3.53. Over the last five days, the stock has lost -17.14%. Mereo Biopharma Group Plc ADR shares have risen nearly 52.81% since the year began. Nevertheless, the stocks have risen 60.45% over the past one year.
Levels Of Support And Resistance For MREO Stock
The 24-hour chart illustrates a support level at 3.42, which if violated will result in even more drops to 3.30. On the upside, there is a resistance level at 3.73. A further resistance level may holdings at 3.93. The Relative Strength Index (RSI) on the 14-day chart is 28.71, which indicates oversold technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.29, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 97.19%. Stochastics %K at 9.03% indicates the stock is a buying.
How much short interest is there in Mereo Biopharma Group Plc ADR?
A steep rise in short interest was recorded in Mereo Biopharma Group Plc ADR stocks on 2024-10-31, dropping by -0.32 million shares to a total of 4.57 million shares. Yahoo Finance data shows the prior-month short interest on 2024-09-30 was 4.88 million shares. There was a decline of -6.92%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on April 05, 2021 when Needham began covering the stock and recommended ‘”a Buy”‘ rating along with a $10 price target.
